EA033231B1 - Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad - Google Patents

Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad

Info

Publication number
EA033231B1
EA033231B1 EA201700138A EA201700138A EA033231B1 EA 033231 B1 EA033231 B1 EA 033231B1 EA 201700138 A EA201700138 A EA 201700138A EA 201700138 A EA201700138 A EA 201700138A EA 033231 B1 EA033231 B1 EA 033231B1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
chronic
patients
aspirin
treatment modality
Prior art date
Application number
EA201700138A
Other languages
Russian (ru)
Other versions
EA201700138A1 (en
Inventor
Юлия Евгеньевна Еременко
Анна Николаевна Котович
Original Assignee
Государственное Учреждение "Республиканский Научно-Практический Центр Оториноларингологии" (Рнпц Оториноларингологии)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное Учреждение "Республиканский Научно-Практический Центр Оториноларингологии" (Рнпц Оториноларингологии) filed Critical Государственное Учреждение "Республиканский Научно-Практический Центр Оториноларингологии" (Рнпц Оториноларингологии)
Priority to EA201700138A priority Critical patent/EA033231B1/en
Publication of EA201700138A1 publication Critical patent/EA201700138A1/en
Publication of EA033231B1 publication Critical patent/EA033231B1/en

Links

Abstract

The invention relates to medicine, namely to otorhinolaryngology, allergology and pulmonology, and is intended for treatment of chronic polypoid rhinosinusitis in patients with aspirin (asthmatic) triad during their post-surgical period. The goal of the declared modality is to increase the effectiveness of treatment by reducing the risk of side effects induced by non-steroid anti-inflammation medications. The essence of the invention is as follows. Following surgical treatment, endonasal mometasone furoate therapy is conducted of paranasal sinuses administering a dose of 100 μg twice a day for a month; next, ketorolac is administered endonasally to the amount of 1.26 mg per dose, 2 – 4 doses per day up each nasal passage for at least two years.
EA201700138A 2017-02-17 2017-02-17 Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad EA033231B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201700138A EA033231B1 (en) 2017-02-17 2017-02-17 Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201700138A EA033231B1 (en) 2017-02-17 2017-02-17 Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad

Publications (2)

Publication Number Publication Date
EA201700138A1 EA201700138A1 (en) 2018-08-31
EA033231B1 true EA033231B1 (en) 2019-09-30

Family

ID=63287029

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700138A EA033231B1 (en) 2017-02-17 2017-02-17 Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad

Country Status (1)

Country Link
EA (1) EA033231B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2403071C1 (en) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Method of treating chronic recurring inflammatory diseases of nasal cavity and paranasal sinises by method of endonasal autolymphocyto therapy
RU2410083C2 (en) * 2003-04-16 2011-01-27 Дей Фарма, Л.П. Compositions and methods of treating rhinosinusitis
US20160367774A1 (en) * 2013-03-26 2016-12-22 Optinose As Nasal administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2410083C2 (en) * 2003-04-16 2011-01-27 Дей Фарма, Л.П. Compositions and methods of treating rhinosinusitis
RU2403071C1 (en) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Method of treating chronic recurring inflammatory diseases of nasal cavity and paranasal sinises by method of endonasal autolymphocyto therapy
US20160367774A1 (en) * 2013-03-26 2016-12-22 Optinose As Nasal administration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ЕРЕМЕНКО Ю.Е. и др. Десенситизация аспирином у пациентов с астматической триадой. Оториноларингология. Восточная Европа, 2016, том 6, № 1, с. 99-105 *
КРЮКОВ А.И. и др. Принципы лечения аллергического ринита. Медицинский совет, 2013, №7, с. 42-47 *

Also Published As

Publication number Publication date
EA201700138A1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
RS52471B (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
HRP20140784T1 (en) Glyx-13 for use in a method of treating refractory depression
JP2009530385A5 (en) Administration of ketamine for the treatment of depression
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
EA201490279A1 (en) KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HRP20240034T1 (en) Treatment of cardiovascular diseases
RU2017119230A (en) TREATMENT OF PIGMENTAL DETROPHY OF THE RETAIL WITH N-ACETYLCYSTEINAMIDE
MX2014001088A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof.
RU2014141893A (en) APPLICATION OF THE PYRAZOLE DERIVATIVE IN THE TREATMENT OF ACUTE ACTIONS OF CHRONIC OBSTRUCTIVE LUNG DISEASE
EA201491460A1 (en) APPLICATION OF LACHINIMODA IN THE TREATMENT OF PATIENTS WITH CRONE'S DISEASE, WHICH ARE NOT EFFECTIVE THERAPY OF THE FIRST LINE ANTI-TNFα
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
WO2012079093A3 (en) Dosage and administration of bispecific scfv conjugates
MX2018013715A (en) Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid.
JP2020516646A5 (en)
MX2016006179A (en) Aqueous based capsaicinoid formulations and methods of manufacture and use.
JP2016505050A5 (en)
RU2012108144A (en) ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES
EA033231B1 (en) Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad
CN102178736B (en) A kind of medicine for the treatment of nasal sinusitis
MX2018009867A (en) Methods comprising fixed intermittent dosing of cediranib.
CL2018003270A1 (en) A pharmaceutical composition comprising carboxylic acid to treat and prevent nasal congestion.
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
Jensen et al. Onset of treatment response to a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU